mitiglinide | 145324-16-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: mitiglinide
• 英文别名: 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid；2-benzyl-3-(transhexahydro-2-isoindolinylcarbonyl)propionic acid；2-benzyl-4-(octahydro-1H-isoindol-2-yl)-4-oxobutanoic acid；4-(1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl)-2-benzyl-4-oxobutanoic acid
• CAS: 145324-16-9
• 化学式: C₁₉H₂₅NO₃
• 分子量: 315.412
• InChiKey: WPGGHFDDFPHPOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  mitiglinide 以 丙醇 、 二氯甲烷 为溶剂， 生成 propyl 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate
  参考文献：
  名称：

  Succinic acid compounds

  摘要：

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.

  公开号：

  US05202335A1

文献信息

• [EN] SUBSTITUTED XANTHINE DERIVATIVES<br/>[FR] DÉRIVÉS DE XANTHINE SUBSTITUÉS
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2013013052A1

  公开（公告）日：2013-01-24

  The present invention in one embodiment relates to a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein: each of R1 and R2 is independently selected from -CH3 and -CD3; R3 is hydrogen or deuterium; each of Z1, Z2 and Z3 is independently selected from hydrogen and deuterium; each Z4 is hydrogen or deuterium; each Z5 is hydrogen or deuterium; and each Z6 is hydrogen or deuterium.

  在一个实施例中，本发明涉及一种化合物，其化学式为（I）；或其药用可接受的盐，其中：R1和R2中的每一个可独立选择自-CH3和-CD3；R3是氢或氘；Z1、Z2和Z3中的每一个可独立选择自氢和氘；每个Z4是氢或氘；每个Z5是氢或氘；每个Z6是氢或氘。
• NOVEL COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE
  申请人：UNIVERSITE PARIS DESCARTES

  公开号：US20200030297A1

  公开（公告）日：2020-01-30

  The invention relates to a compound inhibiting the interaction between a Grb14 protein and an insulin receptor of Formula (I) or Formula (II), their salts, solvates, and/or diastereoisomers, for use for therapeutic purposes, in particular for the treatment of insulin resistance, and to pharmaceutical compositions containing such compounds.

  该发明涉及一种抑制Grb14蛋白与化学式（I）或化学式（II）的胰岛素受体之间相互作用的化合物，其盐、溶剂合物和/或对映异构体，用于治疗目的，特别是用于治疗胰岛素抵抗，并且涉及含有这种化合物的药物组合物。
• Active agent delivery systems and methods for protecting and administering active agents
  申请人：New River Pharmaceuticals Inc.

  公开号：US20040063628A1

  公开（公告）日：2004-04-01

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽的组成部分，与活性物质共价连接的组合物和用于给予共轭活性物质组合物的方法。
• Substituted xanthine derivatives
  申请人：Tung Roger D.

  公开号：US20090239886A1

  公开（公告）日：2009-09-24

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，即取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊酰异丙基黄嘌呤的衍生物。本发明还提供了包含本发明中的一种或多种化合物和载体的组合物，以及把所述化合物和组合物用于治疗戊酰异丙基黄嘌呤和相关化合物有益的疾病和病况的方法。
• [EN] MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR119 ET TRAITEMENT DE TROUBLES LIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2012145604A1

  公开（公告）日：2012-10-26

  The present invention relates to the GPR119 agonist, 4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)-5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidine (Compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及GPR119激动剂4-(1-(5-乙基嘧啶-2-基)哌啶-4-氧基)-5-氟-6-(2-甲基-6-(甲基磺酰基)吡啶-3-氧基)嘧啶（化合物1）及其药学上可接受的盐、溶剂化合物和水合物，这些化合物可用作单一药物或与一个或多个其他药物如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、甲基磺酰基脲、噻唑烷二酮或抗糖尿病肽类似物联合使用，用于治疗例如与GPR119受体相关的疾病；通过增加肠促胰岛素分泌改善的疾病；通过增加血液肠促胰岛素水平改善的疾病；低骨量的疾病；神经系统疾病；代谢相关的疾病；2型糖尿病；肥胖症及其相关并发症。